6-O-Methyl-2,4-bis-O-(trimethylsilyl)erythromycin 9-[O-(1-ethoxy-1-methylethyl)oxime]
CAS 119665-62-2
![Molecular structure of 6-O-Methyl-2,4-bis-O-(trimethylsilyl)erythromycin 9-[O-(1-ethoxy-1-methylethyl)oxime]](https://hantongchem.com/wp-content/themes/hantong/molecules/molecule-images/119665-62-2.png)
CAS · 119665-62-2
Product Overview
6-O-Methyl-2,4-bis-O-(trimethylsilyl)erythromycin 9-[O-(1-ethoxy-1-methylethyl)oxime] is a high-purity pharmaceutical-intermediates supplied for industrial and specialty chemical applications. Contact our team for specifications, packaging options and lead times.
Product Specifications
| Characteristics: | White or off-white crystalline powder |
|---|---|
| Content: | 85.0%–101.0% |
| Solubility: | Complies |
| Identification: | Complies |
| Residue on Ignition: | 0.3% max |
| Methyl s-mop-Oxime: | 2.0% max |
| Total Impurities: | 13% max |
| Water: | 2.0% max |
Applications
6-O-Methyl-2,4-bis-O-(trimethylsilyl)erythromycin 9-[O-(1-ethoxy-1-methylethyl)oxime] (CAS 119665-62-2) is a chemically modified erythromycin derivative primarily used as an intermediate in pharmaceutical synthesis. It is employed in the development and production of semisynthetic macrolide antibiotics with improved pharmacokinetic properties, such as enhanced acid stability, increased oral bioavailability, and extended half-life. This compound serves as a precursor in the preparation of novel erythromycin analogs and related macrolides, enabling medicinal chemists to optimize antibacterial potency and reduce side effects in the treatment of Gram-positive bacterial infections, including respiratory tract and skin infections.
Benefits
The benefits of this compound derive from its chemical modifications, which improve stability, solubility, and reactivity for downstream synthesis. Trimethylsilyl groups protect hydroxyl functionalities during chemical transformations, enabling selective reactions without decomposition of the macrolide core. The oxime modification at position 9 enhances resistance to acidic degradation, allowing for more efficient oral formulations. Its structural versatility facilitates the synthesis of a wide range of erythromycin derivatives, supporting the development of antibiotics with improved efficacy, reduced resistance, and better pharmacokinetic profiles.
Conclusion
6-O-Methyl-2,4-bis-O-(trimethylsilyl)erythromycin 9-[O-(1-ethoxy-1-methylethyl)oxime] is a valuable intermediate in macrolide antibiotic development. Its chemical modifications provide stability, reactivity, and synthetic versatility, enabling the production of semisynthetic erythromycin analogs with enhanced pharmacological properties. By supporting the creation of more effective and stable antibiotics, it remains an essential compound in pharmaceutical research and antibiotic innovation.
Previous
Next